RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2009; 102(03): 609-610
DOI: 10.1160/TH09-04-0257
DOI: 10.1160/TH09-04-0257
Letters to the Editor
Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)
Financial support: Lester M. Meissenheimer was supported by a National Research Foundation (NRF) (South Africa) studentship. This work was supported by the grant G.0540.08 of the fund for Scientific Research-Flanders.
Weitere Informationen
Publikationsverlauf
Received:
22. April 2009
Accepted after minor revision:
16. Juni 2009
Publikationsdatum:
22. November 2017 (online)
-
References
- 1 Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 03: 35-45.
- 2 Hennan JK, Morgan GA, Swillo RE. et al. Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. J Thromb Haemost 2008; 06: 1558-1564.
- 3 Suzuki J, Ogawa M, Muto S. et al. The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury. Expert Opin Ther Targets 2008; 12: 783-794.
- 4 Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731-2738.
- 5 Gils A, Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost 2004; 91: 425-437.
- 6 Ngo TH, Zhou Y, Stassen JM. et al. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition. Thromb Haemost 2002; 88: 288-293.